Abstracts tagged "major histocompatibility complex (MHC) and systemic sclerosis"

Abstract Number: 176 • 2013 ACR/ARHP Annual Meeting
Identification Of Major Histocompatibility Complex Class II Alleles Associated With Systemic Sclerosis Through Imputation Strategy
Jose Ezequiel Martin¹, Carmen P. Simeón², Norberto Ortego-Centeno³, Patricia Carreira⁴, Miguel A. Gonzalez-Gay^5,6, Nicolas Hunzelmann⁷, Shervin Assassi⁸, Filemon K. Tan⁸, Frank C. Arnett⁸, Xiaodong Zhou⁸, T.R.D.J. Radstake^9,10, Maureen D. Mayes¹¹, Paul de Bakker^12,13, Javier Martin^1,14 and B. P. C. Koeleman¹³, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²Department of Internal Medicine, Hospital Valle de Hebron, Barcelona, Spain, ³Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ⁴Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IFIMAV, Santander, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁷Department of Dermatology, University of Cologne, Cologne, Germany, ⁸Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁹Laboratory for Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ¹⁰Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹¹University of Texas Health Science Center at Houston, Houston, TX, ¹²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹³Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁴Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain
Background/Purpose: Different alleles of MHC class II molecules have been associated either with risk to systemic sclerosis (SSc) or its subphenotypes. Due to the high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].